Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 370

1.

Prefrontal cortex activation during obstacle negotiation: What's the effect size and timing?

Maidan I, Shustak S, Sharon T, Bernad-Elazari H, Geffen N, Giladi N, Hausdorff JM, Mirelman A.

Brain Cogn. 2018 Feb 15;122:45-51. doi: 10.1016/j.bandc.2018.02.006. [Epub ahead of print]

PMID:
29454975
2.

Who will remain tremor dominant? The possible role of cognitive reserve in the time course of two common Parkinson's disease motor subtypes.

Herman T, Shema-Shiratzky S, Arie L, Giladi N, Hausdorff JM.

J Neural Transm (Vienna). 2018 Feb 15. doi: 10.1007/s00702-018-1859-3. [Epub ahead of print]

PMID:
29450651
3.

Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.

Dagan M, Herman T, Harrison R, Zhou J, Giladi N, Ruffini G, Manor B, Hausdorff JM.

Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300. [Epub ahead of print]

PMID:
29436740
4.

Progression in the LRRK2-Asssociated Parkinson Disease Population.

Saunders-Pullman R, Mirelman A, Alcalay RN, Wang C, Ortega RA, Raymond D, Mejia-Santana H, Orbe-Reilly M, Johannes BA, Thaler A, Ozelius L, Orr-Urtreger A, Marder KS, Giladi N, Bressman SB; LRRK2 Ashkenazi Jewish Consortium.

JAMA Neurol. 2018 Jan 8. doi: 10.1001/jamaneurol.2017.4019. [Epub ahead of print]

PMID:
29309488
5.

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease.

San Luciano M, Wang C, Ortega RA, Giladi N, Marder K, Bressman S, Saunders-Pullman R; Michael J Fox Foundation LRRK2 Consortium.

Ann Clin Transl Neurol. 2017 Oct 19;4(11):801-810. doi: 10.1002/acn3.489. eCollection 2017 Nov.

6.

Age-associated changes in obstacle negotiation strategies: Does size and timing matter?

Maidan I, Eyal S, Kurz I, Geffen N, Gazit E, Ravid L, Giladi N, Mirelman A, Hausdorff JM.

Gait Posture. 2018 Jan;59:242-247. doi: 10.1016/j.gaitpost.2017.10.023. Epub 2017 Oct 27.

PMID:
29096267
7.

Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.

Balash Y, Bar-Lev Schleider L, Korczyn AD, Shabtai H, Knaani J, Rosenberg A, Baruch Y, Djaldetti R, Giladi N, Gurevich T.

Clin Neuropharmacol. 2017 Nov/Dec;40(6):268-272. doi: 10.1097/WNF.0000000000000246.

8.

Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.

Zitser J, Peretz C, Ber David A, Shabtai H, Ezra A, Kestenbaum M, Brozgol M, Rosenberg A, Herman T, Balash Y, Gadoth A, Thaler A, Stebbins GT, Goetz CG, Tilley BC, Luo ST, Liu Y, Giladi N, Gurevich T.

Parkinsonism Relat Disord. 2017 Dec;45:7-12. doi: 10.1016/j.parkreldis.2017.09.012. Epub 2017 Sep 24.

PMID:
28965872
9.

Disparate effects of training on brain activation in Parkinson disease.

Maidan I, Rosenberg-Katz K, Jacob Y, Giladi N, Hausdorff JM, Mirelman A.

Neurology. 2017 Oct 24;89(17):1804-1810. doi: 10.1212/WNL.0000000000004576. Epub 2017 Sep 27.

PMID:
28954877
10.

Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study.

Arie L, Herman T, Shema-Shiratzky S, Giladi N, Hausdorff JM.

J Neurol. 2017 Oct;264(10):2149-2157. doi: 10.1007/s00415-017-8605-x. Epub 2017 Sep 6.

PMID:
28879438
11.

Reduced mind wandering in patients with Parkinson's disease.

Geffen T, Thaler A, Gilam G, Ben Simon E, Sarid N, Gurevich T, Giladi N, Shabtai H, Zitser J, Schilman EA, Sharon H.

Parkinsonism Relat Disord. 2017 Nov;44:38-43. doi: 10.1016/j.parkreldis.2017.08.030. Epub 2017 Sep 1.

PMID:
28877857
12.

Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites.

Zitser J, Thaler A, Inbar N, Gad A, Faust-Socher A, Paleacu D, Anca-Herschkovitch M, Balash Y, Shabtai H, Ash EL, Merkin L, Manor Y, Kestenbaum M, Bar David A, Peretz C, Naiman T, Bar-Shira A, Orr-Urtreger A, Dangoor N, Giladi N, Gurevich T.

Neurodegener Dis. 2017;17(6):281-285. doi: 10.1159/000479375. Epub 2017 Aug 25.

PMID:
28848105
13.

Schema benefit vs. proactive interference: Contradicting behavioral outcomes and coexisting neural patterns.

Oren N, Shapira-Lichter I, Lerner Y, Tarrasch R, Hendler T, Giladi N, Ash EL.

Neuroimage. 2017 Sep;158:271-281. doi: 10.1016/j.neuroimage.2017.07.006. Epub 2017 Jul 5.

PMID:
28689053
14.

Estimation of genetic risk function with covariates in the presence of missing genotypes.

Lee AJ, Marder K, Alcalay RN, Mejia-Santana H, Orr-Urtreger A, Giladi N, Bressman S, Wang Y.

Stat Med. 2017 Sep 30;36(22):3533-3546. doi: 10.1002/sim.7376. Epub 2017 Jun 27.

PMID:
28656686
15.

Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.

Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, Corvol JC, Brice A, Lesage S, Mangone G, Tolosa E, Pont-Sunyer C, Vilas D, Schüle B, Kausar F, Foroud T, Berg D, Brockmann K, Goldwurm S, Siri C, Asselta R, Ruiz-Martinez J, Mondragón E, Marras C, Ghate T, Giladi N, Mirelman A, Marder K; Michael J. Fox LRRK2 Cohort Consortium.

Mov Disord. 2017 Oct;32(10):1432-1438. doi: 10.1002/mds.27059. Epub 2017 Jun 22.

PMID:
28639421
16.

The role of the prefrontal cortex in freezing of gait in Parkinson's disease: insights from a deep repetitive transcranial magnetic stimulation exploratory study.

Dagan M, Herman T, Mirelman A, Giladi N, Hausdorff JM.

Exp Brain Res. 2017 Aug;235(8):2463-2472. doi: 10.1007/s00221-017-4981-9. Epub 2017 May 16.

PMID:
28509934
17.

When is Higher Level Cognitive Control Needed for Locomotor Tasks Among Patients with Parkinson's Disease?

Maidan I, Bernad-Elazari H, Giladi N, Hausdorff JM, Mirelman A.

Brain Topogr. 2017 Jul;30(4):531-538. doi: 10.1007/s10548-017-0564-0. Epub 2017 Apr 24.

PMID:
28439757
18.

Effects of aging on prefrontal brain activation during challenging walking conditions.

Mirelman A, Maidan I, Bernad-Elazari H, Shustack S, Giladi N, Hausdorff JM.

Brain Cogn. 2017 Jul;115:41-46. doi: 10.1016/j.bandc.2017.04.002. Epub 2017 Apr 21.

PMID:
28433922
19.

Focused and Sustained Attention Is Modified by a Goal-Based Rehabilitation in Parkinsonian Patients.

Ferrazzoli D, Ortelli P, Maestri R, Bera R, Gargantini R, Palamara G, Zarucchi M, Giladi N, Frazzitta G.

Front Behav Neurosci. 2017 Mar 31;11:56. doi: 10.3389/fnbeh.2017.00056. eCollection 2017.

20.

DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.

Artzi M, Even-Sapir E, Lerman Shacham H, Thaler A, Urterger AO, Bressman S, Marder K, Hendler T, Giladi N, Ben Bashat D, Mirelman A.

PLoS One. 2017 Apr 13;12(4):e0175424. doi: 10.1371/journal.pone.0175424. eCollection 2017.

Supplemental Content

Loading ...
Support Center